Skip to main content
Top
Published in: Familial Cancer 2/2022

01-04-2022 | Magnetic Resonance Imaging | Short Communication

Von Hippel-Lindau disease and rapidly progressing pheochromocytomas in siblings

Authors: Ioana Fugaru, Catherine Goudie, John-Paul Capolicchio

Published in: Familial Cancer | Issue 2/2022

Login to get access

Abstract

Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited condition with a predisposition to the development of a variety of tumors including pheochromocytomas. A number of cancer surveillance protocols for patients with VHL have been developed, all of which are based on expert opinion. We report a case of two brothers with a strong family history of VHL type 2 due to a pathogenic germline VHL variant, specifically, a surface missense substitution, with a rapidly progressive clinical course that both presented with a large adrenal mass. Both brothers presented with large pheochromocytomas, the earliest presentation being at age 7, despite routine screening. The rapid progression and early presentation of these patients raises an important discussion around the commonly used surveillance protocols for pheochromocytoma in pediatric patients with VHL and missense mutations. We conclude that a more accelerated surveillance protocol may be adequate for VHL families with a high pheochromocytoma risk.
Literature
1.
go back to reference Maher ER, Iselius L, Yates JR et al (1991) Von Hippel-Lindau disease: a genetic study. J Med Genet 28(7):443–447CrossRef Maher ER, Iselius L, Yates JR et al (1991) Von Hippel-Lindau disease: a genetic study. J Med Genet 28(7):443–447CrossRef
2.
go back to reference Nordstrom-O’Brien M, van der Luijt RB, van Rooijen E et al (2010) Genetic analysis of von Hippel-Lindau disease. Hum Mutat 31(5):521–537PubMed Nordstrom-O’Brien M, van der Luijt RB, van Rooijen E et al (2010) Genetic analysis of von Hippel-Lindau disease. Hum Mutat 31(5):521–537PubMed
3.
go back to reference Pulcrano M, Camera L, Pagano L et al (2008) Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. J Endocrinol Invest 31(4):352–359CrossRef Pulcrano M, Camera L, Pagano L et al (2008) Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. J Endocrinol Invest 31(4):352–359CrossRef
4.
go back to reference Wong WT, Agron E, Coleman HR et al (2007) Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol 125(2):239–245CrossRef Wong WT, Agron E, Coleman HR et al (2007) Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol 125(2):239–245CrossRef
5.
go back to reference Ong KR, Woodward ER, Killick P et al (2007) Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28(2):143–149CrossRef Ong KR, Woodward ER, Killick P et al (2007) Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28(2):143–149CrossRef
6.
go back to reference Eassa W, El-Sherbiny M, Jednak R et al (2012) The anterior approach to retroperitoneoscopic adrenalectomy in children: technique. J Pediatr Urol 8(1):35–39CrossRef Eassa W, El-Sherbiny M, Jednak R et al (2012) The anterior approach to retroperitoneoscopic adrenalectomy in children: technique. J Pediatr Urol 8(1):35–39CrossRef
7.
go back to reference Hes FJ, van der Luijt RB, Lips CJ (2001) Clinical management of Von Hippel-Lindau (VHL) disease. Neth J Med 59(5):225–234CrossRef Hes FJ, van der Luijt RB, Lips CJ (2001) Clinical management of Von Hippel-Lindau (VHL) disease. Neth J Med 59(5):225–234CrossRef
8.
go back to reference Rednam SP, Erez A, Druker H et al (2017) Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23(12):e68–e75CrossRef Rednam SP, Erez A, Druker H et al (2017) Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23(12):e68–e75CrossRef
9.
go back to reference Alliance VHL (2015) The VHL handbook. VHL Alliance, Boston, MA Alliance VHL (2015) The VHL handbook. VHL Alliance, Boston, MA
10.
go back to reference Binderup ML, Bisgaard ML, Harbud V et al (2013) Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J 60(12):B4763PubMed Binderup ML, Bisgaard ML, Harbud V et al (2013) Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J 60(12):B4763PubMed
11.
go back to reference Volkin D, Yerram N, Ahmed F et al (2012) Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome. J Pediatr Surg 47(11):2077–2082CrossRef Volkin D, Yerram N, Ahmed F et al (2012) Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome. J Pediatr Surg 47(11):2077–2082CrossRef
12.
go back to reference Benhammou JN, Boris RS, Pacak K et al (2010) Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol 184(5):1855–1859CrossRef Benhammou JN, Boris RS, Pacak K et al (2010) Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol 184(5):1855–1859CrossRef
13.
go back to reference Feng F, Zhu Y, Wang X et al (2011) Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185(5):1583–1590CrossRef Feng F, Zhu Y, Wang X et al (2011) Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185(5):1583–1590CrossRef
14.
go back to reference Fagundes GFC, Petenuci J, Lourenco DM Jr et al (2019) New insights into pheochromocytoma surveillance of young patients with VHL missense mutations. J Endocr Soc 3(9):1682–1692CrossRef Fagundes GFC, Petenuci J, Lourenco DM Jr et al (2019) New insights into pheochromocytoma surveillance of young patients with VHL missense mutations. J Endocr Soc 3(9):1682–1692CrossRef
15.
go back to reference Nielsen SM, Rubinstein WS, Thull DL et al (2011) Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations. Am J Med Genet A 155A(1):168–173CrossRef Nielsen SM, Rubinstein WS, Thull DL et al (2011) Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations. Am J Med Genet A 155A(1):168–173CrossRef
Metadata
Title
Von Hippel-Lindau disease and rapidly progressing pheochromocytomas in siblings
Authors
Ioana Fugaru
Catherine Goudie
John-Paul Capolicchio
Publication date
01-04-2022
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2022
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-021-00252-2

Other articles of this Issue 2/2022

Familial Cancer 2/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine